NEW YORK (GenomeWeb News) - Nanogen has submitted an influenza diagnostic to the US Centers for Disease Control and Prevention for evaluation for further development, the company said today.
 
Nanogen said this submission fulfills a second-phase milestone requirement on a contract CDC awarded to Nanogen and its business partner, the San Francisco-based HX Diagnostics.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.